Search Results

Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP).

Cara Therapeutics, Inc., a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the first quarter ended March 31, 2024.

Cara Therapeutics, Inc., a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close.

Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.

Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.

Cara Therapeutics, Inc. today announced the Company will host a virtual key opinion leader (KOL) event titled “Meet the NP Experts” on Wednesday, March 27, 2024, at 10:00 a.m. EDT.

Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update.

Cara Therapeutics, Inc. today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses.

Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.